Kezar Life Sciences, Inc.

KZR

NASDAQ

Healthcare

Biotechnology

South San Francisco, CA, US55 employeeskezarlifesciences.com

$7.40

+0.01(0.20%)

Mkt Cap $54M

$3.59

$7.45

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Reportable Segment (100%).

8-K

Kezar Life Sciences terminated its office lease early for ~$2M and entered separation agreements with CEO Kirk, CFO Belsky, and COO Schiller tied to a pending merger with Aurinia Pharma.

$54M

Market Cap

—

Revenue

-$62M

Net Income

Employees55

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($7M)

Activity

What Changed Recently

Material Agreement

Apr 2, 2026

Termination of a Material Definitive Agreement. On April 1, 2026, Kezar Life Sciences, Inc. (the “Company”) entered into a lease termination agreement (the “Lea

Material Agreement

Mar 29, 2026

| Entry into a Material Definitive Agreement. | |---|---| Agreement and Plan of Merger On March 30, 2026, Kezar Life Sciences, Inc., a Delaware corporation (the

Asset Acquisition+3 More

Mar 11, 2026

Entry into a Material Definitive Agreement. On March 6, 2026, Kezar Life Sciences, Inc. (the “Company”) and Enodia Therapeutics SAS, a French simplified joint s

Peer Companies

Company	Price	Change	Market Cap	P/E
MRSNMRSN	$29.08	+0.00%	$145M	—
OKUROnKure Therapeutics, Inc.	$4.32	+6.02%	$59M	-0.9
XLOXilio Therapeutics, Inc.	$8.55	+0.83%	$49M	—
ALGSAligos Therapeutics, Inc.	$7.86	+1.55%	$49M	-2.9
XFORX4 Pharmaceuticals, Inc.	$4.22	-2.99%	$48M	-5.7
FGENFGEN	$9.07	-1.63%	$37M	—
PDSBPDS Biotechnology Corpora...	$0.63	+4.70%	$35M	-0.8
ATNMActinium Pharmaceuticals,...	$0.98	-0.89%	$31M	—

Analyst View

Company Profile

CIK0001645666

ISINUS49372L2097

CUSIP49372L100

Phone650 822 5600

Address4000 Shoreline Court, South San Francisco, CA, 94080, US

SEC EDGAR